Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Treatment-free remission in patients with chronic myeloid leukemia following the second discontinuation of tyrosine kinase inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

WLWeiming Li

Discussion

Loading...

Member takes

Overview

Retrospective analysis found second treatment-free remission feasible in chronic myeloid leukemia, indicating significant molecular response outcomes.

Key Points

  • 33.3% of patients re-initiated TKI therapy after a second discontinuation due to molecular relapse.
  • Multivariate analysis identified first molecular relapse over 4 months as a predictor of successful treatment-free remission.
  • Median duration of molecular response before first TKI discontinuation was 52 months; all patients survived at final follow-up.
  • The analysis involved 39 patients across three institutions, focusing on second treatment-free remission outcomes.

Cite This Study

Weiming Li (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbe9https://doi.org/10.1182/blood-2025-7302
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predictors of successful tirosine kinase inhibitor discontinuation in chronic myeloid leukemia: Long-term, real-world evidence on the role of faster molecular decline and duration of response2025
  2. 2Real-World Evidence-Based Study on Treatment-Free Remission in Chronic Myeloid Leukemia2026
  3. 3Clinical Features and T‐Cell Repertoire of Chronic Myeloid Leukemia Patients Who Attempt Discontinuation of Tyrosine Kinase Inhibitors: The ISAC ‐ TFR Study2025 · 2 citations
  4. 4Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukemia in the chronic phase: Result of JALSG CML RE-STOP219 study.2025
  5. 5Five-year interim analysis of multi-institutional collaborative study for estimating the persistence of treatment free remission in chronic myeloid leukemia after stopping tyrosine kinase inhibitor in Japan: J-SKI2025 · 1 citations